États-Unis · Plateformes & données · MarketBeat

Moderna Melanoma Therapy Cuts Recurrence Risk 42% in Phase 3 Trial

Publié par MarketBeat · États-Unis il y a 1 h

Moderna (NASDAQ:MRNA) presented Phase 3 results for intismeran, its individualized neoantigen therapy, in combination with Merck’s pembrolizumab for patients with resected…

Lire l'article complet sur MarketBeat Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.marketbeat.com)

Moderna Melanoma Therapy Cuts Recurrence Risk 42% in Phase 3 Trial

À lire aussi

Is Berkshire Bending the Rules With Bending Spoons?

Musk says Ukraine violated Starlink terms with offensive drone strikes

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

Lula, Bolsonaro rally supporters on final day before Brazil presidential runoff

First Interstate BancSystem: 3 Key Takeaways for Long-Term Investors

Bank of America resets Tesla forecast as Robotaxi miles double

Moderna Melanoma Therapy Cuts Recurrence Risk 42% in Phase 3 Trial

Partager

À lire aussi

Is Berkshire Bending the Rules With Bending Spoons?

Musk says Ukraine violated Starlink terms with offensive drone strikes

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

Lula, Bolsonaro rally supporters on final day before Brazil presidential runoff

First Interstate BancSystem: 3 Key Takeaways for Long-Term Investors

Bank of America resets Tesla forecast as Robotaxi miles double